Cetuximab and Irinotecan for Advanced Colorectal Cancer
Author Information
Author(s): Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, Tonini G
Primary Institution: Campus Bio-Medico University
Hypothesis
Does the combination of cetuximab and irinotecan provide effective treatment for advanced colorectal cancer patients who have failed previous therapies?
Conclusion
Cetuximab combined with irinotecan shows clinically significant activity in heavily pretreated colorectal cancer patients.
Supporting Evidence
- Cetuximab showed a response rate of 25.4% in the study.
- The overall disease control rate was 63.6%.
- The median time to progression was 4.7 months.
- The median overall survival time was 9.8 months.
- Skin toxicity was observed in 89.1% of patients, with 32.6% experiencing severe reactions.
Takeaway
This study tested a new treatment for patients with advanced colon cancer who didn't respond to other treatments, and it worked for some of them.
Methodology
This was a single center phase II trial evaluating the efficacy and safety of cetuximab combined with irinotecan in patients with EGFR-positive colorectal cancer.
Potential Biases
Potential bias due to the single-center design and lack of randomization.
Limitations
The study was limited to a single center and included only patients with EGFR-positive tumors.
Participant Demographics
Participants included 55 patients, median age 63 years, with 34 colon and 11 rectal cancer cases, and a male-to-female ratio of 16:29.
Statistical Information
P-Value
0.006
Confidence Interval
95% CI: 21.7–39.6%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website